GeneFab, a contract manufacturing and synthetic biology biofoundry focused on cell and gene therapies, signed an agreement with Senti Biosciences under which GeneFab will sublease Senti Bio’s cGMP facility. GeneFab would also acquire Senti Bio’s chemistry, manufacturing, and controls (CMC) capabilities for a total deal of approximately $38 million. Departing Senti Bio co-founder and CTO, Philip Lee, PhD, has become the CEO of GeneFab.

GeneFab will operate from a 92,000 ft² cGMP manufacturing facility in Alameda, CA, that includes 42,000 ft² dedicated to the manufacturing of Phase I/II clinical trial materials. The facility has additional capacity to support complex cell and gene therapy manufacturing, including allogeneic and autologous cell therapy, viral vector, and cell banking, according to Lee.

GeneFab will operate from a 92,000 ft² cGMP manufacturing facility in Alameda, CA, that includes 42,000 ft² dedicated to the manufacturing of Phase I/II clinical trial materials. The facility has additional capacity to support complex cell and gene therapy manufacturing, including allogeneic and autologous cell therapy, viral vector, and cell banking, according to Lee.

omit 

[2023.8.11, Genenews, https://www.genengnews.com/news/genefab-subleases-senti-biosciences-cgmp-facility/]